Antithrombotic drugs and subarachnoid haemorrhage risk

Summary

The study objective was to investigate the relationship between use of antithrombotic drugs and subarachnoid haemorrhage (SAH). We identified patients discharged from Danish neurosurgery units with a first-ever SAH diagnosis in 2000 to 2012 (n=5,834). For each case, we selected 40 age-, sex- and period-matched population controls. Conditional logistic regression models were used to estimate odds ratios (aOR), adjusted for comorbidity, education level, and income. Low-dose aspirin (ASA) use for < 1 month was associated with an increased risk of SAH (aOR 1.75, 95% confidence interval [CI] 1.28–2.40). This aOR decreased to 1.26 (95%CI: 0.98–1.63) with 2–3 months of ASA use, and approached unity with use for more than three months (1.11, 95%CI 0.97–1.27). Analyses with first-time users confirmed this pattern, which was also observed for clopidogrel. ASA treatment for three or more years was associated with an aOR of SAH of 1.13 (95%CI: 0.86–1.49). Short-term use (< 1 month) of vitamin K-antagonists (VKA) yielded an aOR of 1.85 (95%CI 0.97–3.51) which dropped after 3+ years to 1.24, 95%CI: 0.86–1.77. The risk of SAH was higher in subjects in dual antithrombotic treatment (aOR 2.08, 95%CI: 1.26–3.44), and in triple antithrombotic treatment (aOR 5.74, 95%CI: 1.76–18.77). In conclusion, use of aspirin,clopidogrel and VKA were only associated with an increased risk of SAH in the first three months after starting treatment. Long-term aspirin use carried no reduced SAH risk. Results should be interpreted cautiously due to their observational nature.

Keywords

Anticoagulants - aspirin - clopidogrel - platelet aggregation inhibitors - subarachnoid haemorrhage

• References

• 1 Schievink WI. Intracranial aneurysms. N Engl J Med 1997; 336: 28-40.
• 2 González-Pérez A, Gaist D, Wallander M-A. et al. Mortality after haemorrhagic stroke: data from general practice (The Health Improvement Network). Neurology 2013; 81: 559-565.
• 3 Vlak MHM, Rinkel GJE, Greebe P. et al. Lifetime risks for aneurysmal subarachnoid haemorrhage: multivariable risk stratification. J Neurol Neurosurg Psychiatry 2013; 84: 619-623.
• 4 Olsen M, Johansen MB, Christensen S. et al. Use of vitamin K antagonists and risk of subarachnoid haemorrhage: a population-based case-control study. Eur J Intern Med 2010; 21: 297-300.
• 5 Schmidt M, Johansen MB, Lash TL. et al. Antiplatelet drugs and risk of subarachnoid haemorrhage: a population-based case-control study. J Thromb Haemost JTH 2010; 8: 1468-1474.
• 6 Risselada R, Straatman H, van Kooten F. et al. Platelet aggregation inhibitors, vitamin K antagonists and risk of subarachnoid haemorrhage. J Thromb Haemost 2011; 9: 517-523.
• 7 Garcia-Rodriguez LA, Gaist D, Morton J. et al. Antithrombotic drugs and risk of haemorrhagic stroke in the general population. Neurology 2013; 81: 566-574.
• 8 Hasan DM, Mahaney KB, Brown RD. et al. Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture. Stroke J Cereb Circ 2011; 42: 3156-3162.
• 9 Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-33.
• 10 Gaist D, Vaeth M, Tsiropoulos I. et al. Risk of subarachnoid haemorrhage in first degree relatives of patients with subarachnoid haemorrhage: follow up study based on national registries in Denmark. Br Med J 2000; 320: 141-145.
• 11 Rothman K, Geenland S, Lash T. editors. Modern Epidemiology. 3rd ed. Philadelphia, PA: Wolters Kluwer Health, Lippencott Williams & Wilkins; 2008
• 12 Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22-25.
• 13 Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39: 38-41.
• 14 Ref. program. Referenceprogam for behandling af patienter med apopleksi og TCI (2013) Danish Stroke Society. http://www.dsfa.dk/wpcontent/uploads/REFERENCEPR0GRAMFINAL20131.pdf (in Danish) 2013
• 15 Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health 2011; 39: 91-94.
• 16 Thygesen LC, Daasnes C, Thaulow I. et al. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 2011; 39: 12-16.
• 17 Chalouhi N, Ali MS, Jabbour PM. et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 2012; 32: 1659-1676.
• 18 Hasan D, Hashimoto T, Kung D. et al. Upregulation of cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in wall of ruptured human cerebral aneurysms: preliminary results. Stroke J Cereb Circ 2012; 43: 1964-1967.
• 19 Hasan DM, Chalouhi N, Jabbour P. et al. Evidence that acetylsalicylic acid attenuates inflammation in the walls of human cerebral aneurysms: preliminary results. J Am Heart Assoc 2013; 2: e000019.
• 20 De Rooij NK, Linn FHH, van der Plas JA. et al. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007; 78: 1365-1372.
• 21 Statens Serum Institut. “Medstat.dk.”. Accessed June 6 2015 http://www.medstat.dk/en.